Business Context and Reporting Period
Company: Processa Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 20, 2020
Event: Entry into a Material Definitive Agreement (Item 1.01) and Regulation FD Disclosure (Item 7.01).
Key Financial Metrics
This filing reports a strategic transaction rather than periodic financial performance. Consequently, the document does not provide revenue, profit, cash flow, margins, debt, or liquidity figures for the reporting period.
- Immediate Consideration: $2 million in Processa common stock issued to Yuhan Corporation.
- Future Obligations: Development, regulatory, and sales milestone payments (cash and/or stock) contingent on clinical and commercial success.
- Contingent Increase: Milestone payment amounts increase if Yuhan invests at least $3.0 million in Processa's planned underwritten public offering.
Material Changes
On August 19, 2020, Processa entered into an exclusive global license agreement (excluding South Korea) with Yuhan Corporation for the asset YH12852. This grants Processa rights to develop, manufacture, and commercialize the product. The agreement establishes a joint Processa-Yuhan Board to oversee commercialization efforts.
Outlook, Risks, and Diligence Milestones
Processa is required to use commercially reasonable efforts to meet specific diligence milestones at its sole cost and expense:
- Prepare a first draft of the product development plan within 90 days.
- Request an FDA pre-IND meeting within 6 months.
- Dose a first patient in a Phase 2A clinical trial within 24 months.
- Dose a first patient in a Phase 2B, Phase 3, or other pivotal clinical trial within 48 months.
Risks and Contingencies: The agreement may be terminated by either party for a material breach not cured within 60 days (or 15 days for payment breaches). Future financial obligations are contingent on achieving regulatory approvals and sales thresholds.
Investor Verification Checklist
- Verify the exact number of shares issued for the $2 million initial consideration and the resulting dilution.
- Review the full text of the License Agreement (Exhibit 10.1) for specific dollar amounts of milestone payments and royalty rates.
- Confirm the status of the planned underwritten public offering mentioned as a condition for increased milestone payments.
- Assess the clinical development status of YH12852 to gauge the feasibility of the 90-day and 6-month diligence milestones.